Skip to main content
TipRanks
Go Ultimate75% OFF

Journey Medical Corp (DERM) AI Stock Analysis

122 Followers
DERM

Journey Medical Corp

(NASDAQ:DERM)

Select Model
Rating:46Neutral
Price Target:$3.50▼(-10.26% Downside)
Action:reiterated
Date:11/17/26

Overall score is weighed down primarily by weak financial quality (ongoing net losses and negative free cash flow despite improving revenue and EBITDA) and bearish technicals (price well below key moving averages with negative MACD). Offsetting these, the earnings call tone and operating momentum around Emrosi (prescription/prescriber growth and improving access) are constructive, while valuation remains constrained by a negative P/E and no stated dividend yield.

Positive Factors
Revenue and EBITDA improvementImproving revenue, gross margin, and recurring EBITDA performance indicate that commercial scale is beginning to translate into better operating economics. If sales continue growing faster than expenses, Journey Medical can move closer to sustainable profitability while funding continued investment in its dermatology portfolio.
Negative Factors
Negative cash generationPersistent operating and free-cash-flow deficits mean the business has not yet funded operations internally, despite improving revenue and EBITDA. Continued cash burn can constrain investment flexibility and increase reliance on external capital until positive cash generation becomes consistent.

Journey Medical Corp (DERM) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%DERM-48.28%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$110.08M
Dividend Yield
―
Average Volume (3M)
191.10K
Price to Earnings (P/E)
-19.4
Beta (1Y)
0.59
Revenue Growth
17.03%
EPS Growth
49.40%
Country
US
Employees
58
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Journey Medical Corp Business Overview & Revenue Model

Company Description

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the U...

Journey Medical Corp Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-11.16%|Next Earnings Date:Mar 31, 2027
Earnings Call SentimentPositive

The call was predominantly positive, marked by revenue and net product sales growth, improving gross margin, two consecutive quarters of positive EBITDA, strong Emrosi prescription and prescriber expansion, favorable refill trends, compelling clinical data, and expected payer-access improvements. The company still reported a GAAP loss, a lower cash balance, one-time vendor settlement costs, temporary prescription volatility following a copay change, and incomplete formulary coverage, but management characterized these issues as manageable or nonrecurring while emphasizing continued commercial momentum.

Positive Updates

Revenue Growth and Improved Profitability
Third-quarter total revenue was $19 million versus $15 million in the third quarter of 2025, with management reporting 8% year-over-year growth. Net product sales increased 11% year-over-year, gross margin improved to 69% from 67%, and the company achieved positive EBITDA for the second consecutive quarter.

Negative Updates

One-Time Vendor Settlement Expense
SG&A expenses were $12.6 million versus $12.1 million in the third quarter of 2025, primarily due to a $1.7 million one-time expense related to the settlement of a dispute with a former vendor. Management said the settlement was a one-time cash outlay and is now fully resolved.

Company Guidance

Management expects Emrosi’s key metrics to “continue to trend positively in the coming quarters,” ASP to “trend higher in the coming quarters,” and high-quality coverage to increase from “40% of commercial lives,” or about “170 million, 180 million lives,” after a large national plan covering “over 25 million lives” takes effect at the beginning of 2027; quality coverage means “a single-step or better.” Management expects the plan’s impact to be felt “beginning in Q1,” anticipates an “upward trend on ASP and improvement in gross-to-net as the quarters progress in '27,” expects newly added representatives to have “a good 2 quarters” to become productive, and said prescription volatility after the copay change might take “anywhere from 4 to 8 weeks” to recover. SG&A is expected to be “consistent or a little bit lower as a percentage of revenue,” while management is “probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance” on 2027 revenue or EBITDA.

Journey Medical Corp Financial Statement Overview

Summary

Fundamentals are improving, but still transitional. The Income Statement shows rapid TTM revenue growth and EBITDA turning positive, yet operating profit remains negative and net margin is still around -7%. The Balance Sheet looks more stable with manageable leverage (~0.8x debt/equity) and rebuilt equity, but negative ROE persists. The biggest drag is Cash Flow: TTM operating cash flow and free cash flow are both negative (about -$8.5M), indicating ongoing funding risk until cash generation turns consistently positive.

Income Statement

44Neutral

Balance Sheet

56Neutral

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue69.52M61.86M56.13M79.18M73.67M63.13M
Gross Profit30.03M36.68M35.26M52.52M42.89M31.05M
EBITDA2.74M-3.33M-8.40M1.92M-23.18M-32.77M
Net Income-5.10M-11.43M-14.67M-3.85M-29.63M-43.99M
Balance Sheet
Total Assets103.85M94.59M80.24M76.85M105.16M97.28M
Cash, Cash Equivalents and Short-Term Investments22.32M24.09M20.30M27.44M32.00M49.08M
Total Debt25.62M25.40M25.70M17.73M22.96M9.05M
Total Liabilities71.60M62.74M60.17M56.50M88.18M55.24M
Stockholders Equity32.25M31.85M20.07M20.35M16.98M42.04M
Cash Flow
Free Cash Flow-8.55M-12.44M-24.13M240.00K-33.53M-12.18M
Operating Cash Flow-8.55M-12.44M-9.13M5.24M-13.53M-2.18M
Investing Cash Flow00-15.00M-5.00M-20.00M-10.00M
Financing Cash Flow5.92M16.23M16.99M-4.80M16.46M53.02M

Journey Medical Corp Technical Analysis

Technical Analysis SentimentNegative
Last Price3.90

Price Trends

50DMA5.73Negative
100DMA6.35Negative
200DMA6.39Negative

Market Momentum

MACD-0.47Positive
RSI31.11Neutral
STOCH25.42Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DERM, the sentiment is Negative. The current price of 3.90 is below the 20-day moving average (MA) of 4.66, below the 50-day MA of 5.73, and below the 200-day MA of 6.39, indicating a bearish trend. The MACD of -0.47 indicates Positive momentum. The RSI at 31.11 is Neutral, neither overbought nor oversold. The STOCH value of 25.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DERM.

Journey Medical Corp Risk Analysis

Journey Medical Corp disclosed 62 risk factors in its most recent earnings report. Journey Medical Corp reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.There is substantial doubt regarding our ability to continue as a going concern. We may need to raise additional funding (which may not be available on acceptable terms to the Company, or at all) and/or to delay, limit or terminate certain of our product development and commercialization efforts or other operations.Q4, 2023
2.If the FDA does not conclude that a product candidate satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidate under Section 505(b)(2) are not as we expect, the approval pathway for the product candidate will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.Q4, 2023
3.Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.Q4, 2023

Journey Medical Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DERM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TKNOTKNO56Neutral$481.21M-26.00-24.95%―15.45%12.64%
CPIXCPIX55Neutral$86.97M1.22202.58%23.90%-39.11%-241.27%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TLPHTLPH47Neutral$41.61M-3.21-96.70%―-100.00%46.24%
DERMDERM46Neutral$110.08M-19.36-16.07%―17.03%49.40%

* Healthcare Sector Average

Performance Comparison

0%200%400%DERMTLPHCPIXSXTCTKNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DERM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DERMJourney Medical Corporation3.90-3.75-49.02%
TLPHTalphera, Inc.0.80-0.52-39.39%
CPIXCumberland Pharmaceuticals Inc.5.804.31289.78%
SXTCChina Sxt Pharmaceuticals2.86-1601997.14-100.00%
TKNOAlpha Teknova, Inc.7.653.2373.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026